MARA rated glofitamab (COLUMVI) A (Strong) before HAS published CT opinion CT21596 on 18 March 2026. The A signal correctly predicted that reimbursement would be granted — HAS concluded SMR Important for monotherapy in patients with relapsed or refractory DLBCL after at least two prior lines who had failed or were ineligible for CAR-T therapy. MARA’s HAS signal placed ASMR V well below the dataset baseline (16% vs. 59%), indicating a pricing advantage was historically likely at this profile — but HAS assigned ASMR V, citing the absence of Phase 3 RCT data for the monotherapy dossier and a methodologically inadequate indirect comparison despite a direct comparison being feasible. MARA’s A grade was grounded largely in the STARGLO Phase 3 combination trial (Glofit-GemOx); the HAS evaluated the monotherapy evidence package, which was materially weaker. MARA’s safety domain rated Strong, but HAS flagged frequent cytokine release syndrome, grade 3–4 neutropenia, and severe infections as a material negative.